Metabolic-Toxin-Drug
5 cases on metabolic, nutritional, and drug-toxicity pharmacology — thiamine timing in Wernicke's prevention, serotonin syndrome versus NMS, valproate-induced hyperammonemia, hepatic encephalopathy therapy failure, and lithium neurotoxicity — choose a case below to open its full multi-voice debate.
A pregnant patient with severe hyperemesis arrives critically hypoglycemic and already showing an early sign of thiamine deficiency. The debate isn’t whether she needs thiamine — it’s whether a brief delay to give it first actually protects her, or just feels like it does.
A post-surgical patient develops fever, rigidity, and altered mental status after exposure to both a serotonergic drug and a dopamine-blocking one. His exam doesn’t cleanly point to either syndrome, and the two syndromes require different treatments.
A well-controlled epilepsy patient becomes acutely confused with a valproate level that hasn’t changed and liver enzymes that are normal. The complication hiding behind those reassuring numbers has its own separate cause.
A cirrhotic patient returns with his third hepatic encephalopathy episode in four months, still nominally on lactulose. Whether he has truly failed the drug, or simply couldn’t tolerate taking it as prescribed, changes what happens next.
An older man on stable long-term lithium develops ataxia and a witnessed myoclonic jerk after a new medication and a few days of poor intake. His lithium level looks only mildly elevated — his exam doesn’t.